Hello, we're Nonacus

Your NGS partner in detection, monitoring, and guiding treatment with a validated end-to-end workflow

From Brainstorm to Breakthrough

The Nonacus origin story

Our story begins with two scientists and a genomics problem they wanted to solve.

When Chris Sale and Lee Silcock founded Nonacus in 2015 they had one singular purpose - to develop non-invasive DNA tests that would change the way genomic diagnostics was done.

Based on the Latin term 'non acus' meaning 'no needle', Nonacus symbolises the company's mission- to move away from intrusive, risky diagnostic procedures like tissue biopsies or amniocentesis towards less invasive testing to improve patient experiences, redefine standard of care and open up new possibilities for monitoring and treatment.

GALEAS Bladder, our first truly non-invasive test, is able to detect bladder cancer from a urine sample – not a needle in sight.

 

 

 

 

Chris and Lee Nonacus

Our mission

We’re creating a world where early cancer diagnosis, detection and management is simple and universally available.

A decade of innovation

As Nonacus approaches its 10th anniversary in 2025, it's a testament to what can be achieved by the unwavering ambition of a dedicated team. We've witnessed a remarkable decade of growth and innovation, fuelled by the vision of our co-founders.

Looking ahead, we're excited to embark on the next chapter. This includes expanding our global reach, building a vibrant community of scientists and researchers, and continuously pushing the boundaries of NGS technology.

Jeff Bousfield Nonacus CEO

Meet Jeff, our CEO

"Nonacus is solving problems that’ll improve the lives of billions worldwide through the universal availability of early cancer diagnosis, detection and management. I'm honored to lead this amazing team that has already achieved so much. Together, we will continue to innovate and deliver groundbreaking solutions that transform patient care and advance the future of precision medicine, focusing on improving patient outcomes and making a meaningful difference to people's lives.”

Jeff Bousfield

CEO, Nonacus

Latest Nonacus News

Nonacus introduces its first ultrasensitive qPCR assay for ESR1 mutation detection

Nonacus achieves ISO 27001 certification for GALEAS software

Nonacus Awarded All Wales Medical Genomics Service (AWMGS) Tender for Familial Hypercholesterolaemia Testing

Nonacus Awarded All Wales Medical Genomics Service (AWMGS) Tender for Familial Hypercholesterolaemia Testing

Interested in joining our team?